Developer docs
API playgroundTry for free, no card

Search company profiles

MeCure Industries

Full company profile

uuid0006hb5

Namestring
MeCure Industries
Legal namestring
MeCure Industries PLC
Websiteurl
mecure.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

MeCure Industries PLC is a Lagos-headquartered pharmaceutical manufacturer founded in 2005 and listed on the Nigerian Exchange (NGX) Growth Board under ticker MECURE since November 2023. The company produces over 50 brands and 200+ generic formulations spanning antibiotics, antimalarials, cardiovascular, anti-diabetic, analgesics, multivitamins, and dietary supplements (under the Youthberry brand), manufactured at cGMP-compliant, ISO 9001:2015-certified facilities in Oshodi, Lagos, with multi-format capability across tablets, capsules, dry syrups, stick packs, sachets, and syrups. Proprietary technology includes the GS1-certified Track & Trace system developed with ACG Inspection, which assigns unique 12-digit serial numbers to each product for smartphone-based authentication, and the Liquitab Floatcap tablet-in-capsule formulation.

MeCure operates three revenue streams: (1) direct pharmaceutical product sales to a network of 150+ distributors and pharmacies, supported by four strategically located depots in Lagos, Kano, Onambra/Onitsha, and Abia; (2) the PharmaMart B2B2C e-commerce platform, operated under MeCure Distribution Limited, which sells to wholesalers and pharmacies with credit facilities and free Lagos delivery; and (3) contract manufacturing services for partner companies including TOC Pharma, Venchura Pharmaceutical, High Clout Pharma, and Exxon (Pharmaceutical), covering multiple therapeutic categories and dosage forms. The company's products are sold primarily through its own field sales organization (Medical Sales Representatives, Area Sales Managers, Key Account Managers) and through its distributor network across Nigeria, with stated ambitions for West African expansion.

The company is led by founder and Chairman Samir Udani alongside Co-CEOs Anderline Dukor (Operations) and Arjun Udani (Commercial). In October 2024, Zrosk Investment Management acquired a 10% strategic stake. Recent financial performance has been strong: FY2025 revenue of N77.69 billion (+69% YoY), profit after tax of N6.463 billion (+177.5% YoY), and a 369% YTD stock price gain in 2025 leading the Nigerian pharma sector. MeCure also operates a sister company, MeCure Healthcare Limited, which provides advanced diagnostic services including PET-CT and medical cyclotron facilities in West Africa.

Short descriptiontext

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer producing 50+ brands of antibiotics, generics, and dietary supplements through cGMP-compliant facilities, selling via 150+ distributors, a PharmaMart B2B2C platform, and contract manufacturing services for partner companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLagos, Nigeria
HQ citystring
Lagos
HQ countrystring
Nigeria
HQ regionstring
Africa
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medications, contract manufacturing, pharmaceutical distribution, nutraceutical supplements
Industry1 code
1Compounding Ingredient & API Distributors (Pharma Supply)
CodeHLAIAJAOPrimaryNo
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

MeCure generates revenue primarily through the manufacture and sale of pharmaceutical products including branded generics, OTC medicines, and dietary supplements across therapeutic categories including antibiotics, antimalarials, cardiovascular, analgesics, multivitamins, and nutraceuticals. Revenue is derived from sales to distributors, pharmacies, clinics, healthcare providers, and retail customers across Nigeria and West Africa.

mecure.com
2Contract Manufacturing Services
TypeProfessional Services
Description

MeCure provides end-to-end pharmaceutical contract manufacturing solutions for companies seeking reliable production, regulatory discipline, and market-ready execution. Revenue is generated through manufacturing fees charged to partner companies for product development, commercial production, packaging, and regulatory support.

mecure.com
3PharmaMart B2B2C Platform
TypeTransaction Fee
Description

PharmaMart, operated under MeCure Distribution Limited, serves as a B2B2C e-commerce platform enabling purchase of pharmaceutical products by distributors, wholesalers, pharmacies, and healthcare providers, with credit facilities and delivery services.

mecure.com
4Nutraceutical Sales (Youthberry)
TypeOne Time License
Description

Sale of dietary supplements and wellness products under the Youthberry brand, including multivitamins and nutritional supplements.

mecure.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Individual product pricing on PharmaMart e-commerce platform
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products priced per unit/sachet/roll with quantities available in various pack sizes. Example prices: Lapar Tablets (Paracetamol 500mg) ₦750/sachet (96 tablets/8 sachets), Zevit Tablets ₦380/30 tablets, AugMec Tablets 625mg ₦2,250/14 tablets, Diclofenac Tablets 50mg ₦620/10 tablets, Metformin 500mg ₦1,560/21 tablets, Amlodipine 5mg ₦320/28 tablets, Blood Tone Syrup ₦1,250/200ml, Loperamide Capsules 2mg ₦195/unit.

pharmamart.mecure.com
2Commercial Paper Issuance - N10 billion at 21% effective yield
ModelOtherBilling cadencePay-as-you-go
Notes

MeCure Industries Plc launched a N10 billion commercial paper at 18.19% discount rate with effective annual yield of 21%, for working capital and operational funding purposes.

nairametrics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Youthberry
Description

Nutraceutical line of dietary supplements launched in 2016 to promote wellness

mecure.com
+8 more records
Core offering1 text field

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer that produces and distributes over-the-counter medicines, branded generic pharmaceuticals, and dietary supplements across therapeutic categories including antibiotics, antimalarials, cardiovascular, analgesics, multivitamins, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities, the PharmaMart B2B2C e-commerce distribution platform under MeCure Distribution Limited, and offers end-to-end contract manufacturing services for third-party pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 369% stock price gain in 2025, leading Nigerian pharma sector and outperforming NGX All-Share Index
+4 more records
Product overview1 text field

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer operating as a platform business with three core product lines: (1) Pharmaceutical manufacturing of OTC medicines, branded generics, and dietary supplements under the Youthberry brand; (2) PharmaMart, a B2B2C e-commerce platform for online pharmaceutical sales with logistics and credit facilities; (3) Contract manufacturing services for third-party pharmaceutical companies. The company produces 50+ brands across antibiotics (Laclox, Lamox, Augmec), antimalarials (Winmalar, Artemether/Lumefantrine), cardiovascular (Lisin, Amlodipine, Atorvastatin, Losartan), analgesics (Ebu, Lapar, Zapar, Diclofenac), multivitamins (Zevit, Blood Tone, Vita Ace), and other therapeutic categories. A key differentiator is the Track & Trace smartphone authentication system for product anti-counterfeiting, and the company holds ISO 9001:2015 certification with cGMP-compliant manufacturing facilities.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-08
Description

MeCure partnered with ACG Inspection, a globally recognized Track & Trace solution provider, to implement a GS1-certified Track & Trace system enabling end-to-end pharmaceutical supply chain monitoring with unique 12-digit serialization and smartphone-based product authentication. The partnership strengthens anti-counterfeiting measures and enhances patient safety standards in Nigeria's pharmaceutical landscape.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Cordros Registrars provides share registry services to MeCure Industries PLC, managing all registered information relating to shareholdings including shareholder names, addresses, dividend payment instructions, and annual report distribution. Located at 21 Norman Williams Street, Ikoyi, Lagos.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MeCure Healthcare Limited is a sister company of MeCure Industries PLC, providing advanced diagnostic and treatment services across Nigeria. It is the first in West Africa to introduce cutting-edge diagnostic technology including PET-CT and medical cyclotron facilities for comprehensive cancer care and early diagnosis, supporting MeCure's mission to expand healthcare access.

4TOC Pharma
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Contract manufacturing partnership spanning multiple therapeutic categories and dosage forms. TOC Pharma represents one of the trusted pharmaceutical companies MeCure supports through its contract manufacturing services.

mecure.com
5Venchura Pharmaceutical Limited
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Contract manufacturing partner for pharmaceutical products supported by MeCure's manufacturing capabilities.

mecure.com
6High Clout Pharma Ltd
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Contract manufacturing partner for pharmaceutical products supported by MeCure's manufacturing capabilities.

mecure.com
7Exxon (Pharmaceutical)
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Contract manufacturing partner for pharmaceutical products across multiple therapeutic categories and dosage forms including antibiotics, anti-infectives, cardiovascular, pain management, oral suspensions, tablets, capsules, and liquid formulations.

mecure.com
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Værdi Investor Relations serves as MeCure's investor relations advisers, managing media inquiries, press contact, and corporate communications. Contact: Oluyemisi Lanre-Phillips at [email protected].

Strategic tierCoreTypeOthers
Description

MeCure operates under regulatory oversight of NAFDAC and has collaborated with the agency on Track & Trace implementation. The company acknowledged NAFDAC Director General Prof. Moji Christianah Adeyeye for visionary leadership in advancing Track & Trace solutions for patient safety in Nigeria.

Strategic tierCoreTypeTechnology or Integration
Description

MeCure's Track & Trace system follows GS1 global standards for pharmaceutical traceability. GS1 Nigeria works with NAFDAC to encourage local manufacturers to implement Track & Trace programs, harmonizing critical tracking events and key data elements across the supply chain.

Strategic tierMinorTypeOthers
Description

MeCure partners with LAWMA for solid waste separation, packaging, and recycling from production operations, contributing to environmental sustainability and responsible waste management.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Indian global pharmaceutical company with strong presence in Africa including Nigeria, focused on generics across respiratory, antiretroviral, and chronic disease categories. Comparable to MeCure in generic pharmaceutical focus and African market presence, though operates at global scale with broader therapeutic portfolio and stronger R&D capabilities.

TypeEmerging player
Description

Nigerian pharmaceutical company focused on antimalarials, antibiotics, and consumer health products. Comparable to MeCure in therapeutic focus and target market but smaller scale and more limited distribution and product breadth.

TypeBroad incumbent
Description

Nigerian operation of global biopharmaceutical company AstraZeneca focused on cardiovascular, respiratory, and oncology branded medications. Comparable to MeCure as a pharmaceutical player in Nigeria but with a multinational focus on patented originator drugs rather than locally manufactured generics.

TypeDirect peer
Description

One of Nigeria's largest indigenous pharmaceutical manufacturers with a broad generic portfolio including antibiotics, analgesics, and antimalarials. Comparable to MeCure in therapeutic category coverage, manufacturing scale, and distribution reach via Nigerian wholesalers and pharmacies.

TypeDirect peer
Description

Nigerian pharmaceutical manufacturer listed on the NGX producing branded generics, OTC medicines, and consumer health products. Closely comparable to MeCure in product mix (antibiotics, antimalarials, analgesics, multivitamins), distribution model, and target customer base of Nigerian distributors and pharmacies.

TypeBroad incumbent
Description

South African-headquartered pan-African pharmaceutical manufacturer with strong presence across Sub-Saharan Africa. Comparable to MeCure in African manufacturing footprint, generic and OTC portfolio, and emerging market distribution strategy, though at significantly larger scale and broader geographic reach.

TypeDirect peer
Description

NGX-listed Nigerian pharmaceutical manufacturer with a long operating history producing generics, OTC medicines, and consumer healthcare products. Comparable to MeCure in listed status, local manufacturing focus, and therapeutic portfolio breadth across antibiotics, antimalarials, and chronic disease medications.

TypeDirect peer
Description

Nigerian pharmaceutical manufacturer and distributor listed on NGX with focus on generics and specialty pharmaceuticals. Comparable to MeCure in product categories (antibiotics, cardiovascular, vitamins), regulatory positioning with NAFDAC, and B2B distribution to Nigerian pharmacies and hospitals.

TypeBroad incumbent
Description

NGX-listed subsidiary of GSK producing consumer healthcare and OTC products in Nigeria. Comparable to MeCure in the OTC and consumer health segment but operates as part of a global multinational with broader portfolio, deeper marketing budgets, and imported product lines.

TypeBroad incumbent
Description

Nigerian subsidiary of global pharmaceutical company Sanofi manufacturing and distributing branded pharmaceuticals including diabetes, cardiovascular, and vaccines. Comparable to MeCure in the Nigerian pharmaceutical market but operates with imported and locally manufactured innovator and generic products under a global brand.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MeCure Industries

Pharmaceutical Manufacturingmecure.com

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer producing 50+ brands of antibiotics, generics, and dietary supplements through cGMP-compliant facilities, selling via 150+ distributors, a PharmaMart B2B2C platform, and contract manufacturing services for partner companies.

What MeCure Industries does

MeCure Industries PLC is a Lagos-headquartered pharmaceutical manufacturer founded in 2005 and listed on the Nigerian Exchange (NGX) Growth Board under ticker MECURE since November 2023. The company produces over 50 brands and 200+ generic formulations spanning antibiotics, antimalarials, cardiovascular, anti-diabetic, analgesics, multivitamins, and dietary supplements (under the Youthberry brand), manufactured at cGMP-compliant, ISO 9001:2015-certified facilities in Oshodi, Lagos, with multi-format capability across tablets, capsules, dry syrups, stick packs, sachets, and syrups. Proprietary technology includes the GS1-certified Track & Trace system developed with ACG Inspection, which assigns unique 12-digit serial numbers to each product for smartphone-based authentication, and the Liquitab Floatcap tablet-in-capsule formulation.

MeCure operates three revenue streams: (1) direct pharmaceutical product sales to a network of 150+ distributors and pharmacies, supported by four strategically located depots in Lagos, Kano, Onambra/Onitsha, and Abia; (2) the PharmaMart B2B2C e-commerce platform, operated under MeCure Distribution Limited, which sells to wholesalers and pharmacies with credit facilities and free Lagos delivery; and (3) contract manufacturing services for partner companies including TOC Pharma, Venchura Pharmaceutical, High Clout Pharma, and Exxon (Pharmaceutical), covering multiple therapeutic categories and dosage forms. The company's products are sold primarily through its own field sales organization (Medical Sales Representatives, Area Sales Managers, Key Account Managers) and through its distributor network across Nigeria, with stated ambitions for West African expansion.

The company is led by founder and Chairman Samir Udani alongside Co-CEOs Anderline Dukor (Operations) and Arjun Udani (Commercial). In October 2024, Zrosk Investment Management acquired a 10% strategic stake. Recent financial performance has been strong: FY2025 revenue of N77.69 billion (+69% YoY), profit after tax of N6.463 billion (+177.5% YoY), and a 369% YTD stock price gain in 2025 leading the Nigerian pharma sector. MeCure also operates a sister company, MeCure Healthcare Limited, which provides advanced diagnostic services including PET-CT and medical cyclotron facilities in West Africa.

MeCure Industries firmographics

Firmographics
Name
MeCure Industries
Legal name
MeCure Industries PLC
Website
https://mecure.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
MeCure Industries PLC is a Nigerian pharmaceutical manufacturer producing 50+ brands of antibiotics, generics, and dietary supplements through cGMP-compliant facilities, selling via 150+ distributors, a PharmaMart B2B2C platform, and contract manufacturing services for partner companies.
Ownership category
akta.pro rank

Where MeCure Industries is headquartered

Location

Headquarters

HQ city
Lagos
HQ country
Nigeria
HQ region
Africa

Offices7 records

Markets served

MeCure Industries business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: MeCure generates revenue primarily through the manufacture and sale of pharmaceutical products including branded generics, OTC medicines, and dietary supplements across therapeutic categories including antibiotics, antimalarials, cardiovascular, analgesics, multivitamins, and nutraceuticals. Revenue is derived from sales to distributors, pharmacies, clinics, healthcare providers, and retail customers across Nigeria and West Africa.
  2. Contract Manufacturing Services: MeCure provides end-to-end pharmaceutical contract manufacturing solutions for companies seeking reliable production, regulatory discipline, and market-ready execution. Revenue is generated through manufacturing fees charged to partner companies for product development, commercial production, packaging, and regulatory support.
  3. PharmaMart B2B2C Platform: PharmaMart, operated under MeCure Distribution Limited, serves as a B2B2C e-commerce platform enabling purchase of pharmaceutical products by distributors, wholesalers, pharmacies, and healthcare providers, with credit facilities and delivery services.
  4. Nutraceutical Sales (Youthberry): Sale of dietary supplements and wellness products under the Youthberry brand, including multivitamins and nutritional supplements.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goIndividual product pricing on PharmaMart e-commerce platform
OtherPay-as-you-goCommercial Paper Issuance - N10 billion at 21% effective yield

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

MeCure Industries product offering

Product offering

Core offering

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer that produces and distributes over-the-counter medicines, branded generic pharmaceuticals, and dietary supplements across therapeutic categories including antibiotics, antimalarials, cardiovascular, analgesics, multivitamins, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities, the PharmaMart B2B2C e-commerce distribution platform under MeCure Distribution Limited, and offers end-to-end contract manufacturing services for third-party pharmaceutical companies.

Product overview

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer operating as a platform business with three core product lines: (1) Pharmaceutical manufacturing of OTC medicines, branded generics, and dietary supplements under the Youthberry brand; (2) PharmaMart, a B2B2C e-commerce platform for online pharmaceutical sales with logistics and credit facilities; (3) Contract manufacturing services for third-party pharmaceutical companies. The company produces 50+ brands across antibiotics (Laclox, Lamox, Augmec), antimalarials (Winmalar, Artemether/Lumefantrine), cardiovascular (Lisin, Amlodipine, Atorvastatin, Losartan), analgesics (Ebu, Lapar, Zapar, Diclofenac), multivitamins (Zevit, Blood Tone, Vita Ace), and other therapeutic categories. A key differentiator is the Track & Trace smartphone authentication system for product anti-counterfeiting, and the company holds ISO 9001:2015 certification with cGMP-compliant manufacturing facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Youthberry: Nutraceutical line of dietary supplements launched in 2016 to promote wellness
  • PharmaMart
  • Track & Trace
  • HelloDoc
  • AugMec
  • Lamox
  • Zevit
  • Lapar
  • Ebu

Quantifiable outcome

  • 369% stock price gain in 2025, leading Nigerian pharma sector and outperforming NGX All-Share Index
  • +4 more outcomes

Companies that use MeCure Industries

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

MeCure Industries technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MeCure Industries partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, supporting and minor.

  • ACG InspectioncoreTechnology or Integration · 8 January 2024MeCure partnered with ACG Inspection, a globally recognized Track & Trace solution provider, to implement a GS1-certified Track & Trace system enabling end-to-end pharmaceutical supply chain monitoring with unique 12-digit serialization and smartphone-based product authentication. The partnership strengthens anti-counterfeiting measures and enhances patient safety standards in Nigeria's pharmaceutical landscape.
  • Cordros Registrars LimitedsupportingImplementation/ SI/ Consulting PartnerCordros Registrars provides share registry services to MeCure Industries PLC, managing all registered information relating to shareholdings including shareholder names, addresses, dividend payment instructions, and annual report distribution. Located at 21 Norman Williams Street, Ikoyi, Lagos.
  • MeCure Healthcare LimitedcoreStrategic or Co-development PartnerMeCure Healthcare Limited is a sister company of MeCure Industries PLC, providing advanced diagnostic and treatment services across Nigeria. It is the first in West Africa to introduce cutting-edge diagnostic technology including PET-CT and medical cyclotron facilities for comprehensive cancer care and early diagnosis, supporting MeCure's mission to expand healthcare access.
  • TOC PharmasupportingChannel Partner/ Reseller/ DistributorContract manufacturing partnership spanning multiple therapeutic categories and dosage forms. TOC Pharma represents one of the trusted pharmaceutical companies MeCure supports through its contract manufacturing services.
  • Venchura Pharmaceutical LimitedsupportingChannel Partner/ Reseller/ DistributorContract manufacturing partner for pharmaceutical products supported by MeCure's manufacturing capabilities.
  • High Clout Pharma LtdsupportingChannel Partner/ Reseller/ DistributorContract manufacturing partner for pharmaceutical products supported by MeCure's manufacturing capabilities.
  • Exxon (Pharmaceutical)supportingChannel Partner/ Reseller/ DistributorContract manufacturing partner for pharmaceutical products across multiple therapeutic categories and dosage forms including antibiotics, anti-infectives, cardiovascular, pain management, oral suspensions, tablets, capsules, and liquid formulations.
  • Værdi Investor RelationssupportingImplementation/ SI/ Consulting PartnerVærdi Investor Relations serves as MeCure's investor relations advisers, managing media inquiries, press contact, and corporate communications. Contact: Oluyemisi Lanre-Phillips at [email protected].
  • NAFDAC (National Agency for Food and Drug Administration and Control)coreOthersMeCure operates under regulatory oversight of NAFDAC and has collaborated with the agency on Track & Trace implementation. The company acknowledged NAFDAC Director General Prof. Moji Christianah Adeyeye for visionary leadership in advancing Track & Trace solutions for patient safety in Nigeria.
  • GS1 NigeriacoreTechnology or IntegrationMeCure's Track & Trace system follows GS1 global standards for pharmaceutical traceability. GS1 Nigeria works with NAFDAC to encourage local manufacturers to implement Track & Trace programs, harmonizing critical tracking events and key data elements across the supply chain.
  • Lagos State Waste Management Authority (LAWMA)minorOthersMeCure partners with LAWMA for solid waste separation, packaging, and recycling from production operations, contributing to environmental sustainability and responsible waste management.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

MeCure Industries competitors and assessment

Company assessment

Broad incumbents

  • Cipla Limited: Indian global pharmaceutical company with strong presence in Africa including Nigeria, focused on generics across respiratory, antiretroviral, and chronic disease categories. Comparable to MeCure in generic pharmaceutical focus and African market presence, though operates at global scale with broader therapeutic portfolio and stronger R&D capabilities.
  • AstraZeneca Nigeria: Nigerian operation of global biopharmaceutical company AstraZeneca focused on cardiovascular, respiratory, and oncology branded medications. Comparable to MeCure as a pharmaceutical player in Nigeria but with a multinational focus on patented originator drugs rather than locally manufactured generics.
  • Aspen Pharmacare Holdings Limited: South African-headquartered pan-African pharmaceutical manufacturer with strong presence across Sub-Saharan Africa. Comparable to MeCure in African manufacturing footprint, generic and OTC portfolio, and emerging market distribution strategy, though at significantly larger scale and broader geographic reach.
  • GlaxoSmithKline Consumer Nigeria Plc: NGX-listed subsidiary of GSK producing consumer healthcare and OTC products in Nigeria. Comparable to MeCure in the OTC and consumer health segment but operates as part of a global multinational with broader portfolio, deeper marketing budgets, and imported product lines.
  • Sanofi-Aventis Nigeria Plc: Nigerian subsidiary of global pharmaceutical company Sanofi manufacturing and distributing branded pharmaceuticals including diabetes, cardiovascular, and vaccines. Comparable to MeCure in the Nigerian pharmaceutical market but operates with imported and locally manufactured innovator and generic products under a global brand.

Emerging players

  • Biofem Pharmaceuticals Limited: Nigerian pharmaceutical company focused on antimalarials, antibiotics, and consumer health products. Comparable to MeCure in therapeutic focus and target market but smaller scale and more limited distribution and product breadth.

Direct peers

  • Emzor Pharmaceutical Industries Limited: One of Nigeria's largest indigenous pharmaceutical manufacturers with a broad generic portfolio including antibiotics, analgesics, and antimalarials. Comparable to MeCure in therapeutic category coverage, manufacturing scale, and distribution reach via Nigerian wholesalers and pharmacies.
  • Fidson Healthcare Plc: Nigerian pharmaceutical manufacturer listed on the NGX producing branded generics, OTC medicines, and consumer health products. Closely comparable to MeCure in product mix (antibiotics, antimalarials, analgesics, multivitamins), distribution model, and target customer base of Nigerian distributors and pharmacies.
  • May & Baker Nigeria Plc: NGX-listed Nigerian pharmaceutical manufacturer with a long operating history producing generics, OTC medicines, and consumer healthcare products. Comparable to MeCure in listed status, local manufacturing focus, and therapeutic portfolio breadth across antibiotics, antimalarials, and chronic disease medications.
  • Neimeth International Pharmaceuticals Plc: Nigerian pharmaceutical manufacturer and distributor listed on NGX with focus on generics and specialty pharmaceuticals. Comparable to MeCure in product categories (antibiotics, cardiovascular, vitamins), regulatory positioning with NAFDAC, and B2B distribution to Nigerian pharmacies and hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

MeCure Industries social profiles

Digital presence

MeCure Industries compliance and trust

Trust signal

Compliance2 records

MeCure Industries financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MeCure Industries leadership team

Management profile

Number of profiles

Profiles11 records

MeCure Industries subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

MeCure Industries funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MeCure Industries M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MeCure Industries

What does MeCure Industries do?

MeCure Industries PLC is a Nigerian pharmaceutical manufacturer that produces and distributes over-the-counter medicines, branded generic pharmaceuticals, and dietary supplements across therapeutic categories including antibiotics, antimalarials, cardiovascular, analgesics, multivitamins, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities, the PharmaMart B2B2C e-commerce distribution platform under MeCure Distribution Limited, and offers end-to-end contract manufacturing services for third-party pharmaceutical companies.

Is MeCure Industries a public or private company?

MeCure Industries is a public company. It is classified as public and is currently operating.

When was MeCure Industries founded?

MeCure Industries was founded in 2005. It employs 1,001 to 5,000 people.

Where is MeCure Industries based?

MeCure Industries is headquartered in Lagos, Nigeria, in the Africa region.

How does MeCure Industries make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing Services, pharmaMart B2B2C Platform and nutraceutical Sales (Youthberry).

Who are MeCure Industries's main competitors?

Broad incumbents on record are Cipla Limited, AstraZeneca Nigeria, Aspen Pharmacare Holdings Limited, GlaxoSmithKline Consumer Nigeria Plc and Sanofi-Aventis Nigeria Plc. Biofem Pharmaceuticals Limited is listed as an emerging player. Direct peers are Emzor Pharmaceutical Industries Limited, Fidson Healthcare Plc, May & Baker Nigeria Plc and Neimeth International Pharmaceuticals Plc.

Does MeCure Industries have an API?

No public API is recorded for MeCure Industries.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessdayFunding the short term: Why Commercial Paper belongs on an ExchangeNigerian Exchange Limited introduced a commercial paper listing framework on December 3, 2025, and Dangote Cement listed N119.87 billion in CP in February 2026. Other issuers have followed, with about N89.49 billion listed. The goal is to build secondary-market liquidity and deepen Nigeria's capital market.BusinessdayFrom traction to scale: Financing Nigeria’s high-growth companiesNigeria's NGX Growth Board provides a capital market entry point for companies with market capitalization between N50 million and N4 billion. MeCure Industries, listed in 2023, grew revenue 69% to N77.69 billion by 2025, illustrating the segment's potential. The article argues the board can build a pipeline of emerging businesses to become major Nigerian institutions.BusinessdayMay & Baker outpaces pharma firms in profit margin growthMay & Baker Nigeria's net profit margin rose to 16.59% in H1 2026, up from 11.34%, despite flat revenue. The company's net profit grew 46% to N3.20 billion, outpacing the sector's aggregate margin of 10.24%. Fidson Healthcare ranked second with a 10.37% margin.BusinessdayMeet Anderline Ndidi Dukor, set to lead N224.8bn MeCure IndustriesMeCure Industries' board appointed Anderline Ndidi Dukor as sole CEO and Arjun Udani as Executive Director, Operations & Finance, effective August 1, 2026. The change shifts the company from a dual-CEO model to a single-CEO structure, aiming to improve strategic execution and governance. The pharmaceutical firm is valued at about N224.8 billion on the Nigerian Exchange.Premium Times NigeriaMeCure Plc ends co-CEO leadership structure, appoints new CEO, executive directorMeCure Industries Plc has appointed Anderline Dukor as Chief Executive Officer, replacing the company's co-CEO leadership model with a traditional single CEO structure effective 1 August. The company also appointed Arjun Udani as Executive Director, Operations & Finance, as part of a broader executive reorganization disclosed in a regulatory filing. Following a comprehensive board review of strategic priorities and governance framework, MeCure stated that unified leadership will enhance strategic execution, accelerate decision-making, and strengthen accountability to deliver sustainable growth.NairametricsInsurance stocks rescue NGX as investors recover N481 billionNigerian equities market recovered on Tuesday, July 28, 2026, with investors gaining N481.18 billion as insurance stocks led gains. The All-Share Index rose 0.30% to 247,984.55 points, and market capitalization increased to N159.99 trillion, up 0.30%.Punch NewspapersDrugmakers' Finance Costs Jump 47% Amid High Interest RatesNigerian pharmaceutical companies listed on the Nigerian Exchange recorded a 46.5 per cent increase in combined finance costs in Q1 2026, rising from N2.09bn to N3.07bn compared to the same period in 2025. MeCure Industries led with a 49.5 per cent finance cost increase, while Neimeth and Morison Industries also faced higher borrowing costs amid Nigeria's 26.5 per cent benchmark interest rate. Experts attribute the surge to the high interest rate environment, though MeCure's near-doubling of operating profit and government import duty concessions have helped cushion the impact on some firms.Punch NewspapersNigerian Stock Market Sheds N800bn Amid Profit-TakingThe Nigerian Exchange Limited experienced a significant market correction on Wednesday as aggressive profit-taking wiped N800bn off total market capitalization, with the All-Share Index falling 1,241.19 points (0.50%) to close at 245,418.37 basis points. Key decliners included Nestle Nigeria, BUA Foods, UACN, MeCure Industries, and International Energy Insurance, each dropping between 7.75% and 10%. Despite the broader market contraction, investor sentiment remained resilient with positive market breadth (37 gainers versus 27 decliners) and sustained buying interest in tier-one banking stocks.BusinessdayMeCure Industries seeks N50bn capital raise as profit jumps 177%MeCure Industries proposed raising N50bn from N30bn to fund expansion, after 2025 profit after tax surged 177% to N6.46bn. Revenue rose 69% to N77.69bn, and shareholders approved a 32-kobo dividend. The company expects growth in 2026 from favorable government policies and rising healthcare demand.BusinessdayMeCure Industries gets GCR rating affirmation as H1 growth acceleratesMeCure Industries had its long-term issuer rating affirmed at BBB(NG) and short-term at A3(NG) by GCR Ratings, with outlook revised to stable. The Lagos-based pharma firm closed H1 2026 with improved earnings and market penetration, citing product innovation and wider distribution. It also secured Halal certification and launched two new products.